Literature DB >> 19568708

Study on the relationship between blood stasis syndrome and clinical pathology in 227 patients with primary glomerular disease.

Shen Li1, Xiang-rong Rao, Su-xia Wang, Gai-hua Zhang, Xiao-mei Li, Xi-wen Dai, Ke-ji Chen.   

Abstract

OBJECTIVE: To investigate the relationship between the severity of Chinese medicine (CM) blood stasis syndrome (BSS) with clinical features and renal lesion indexes of the primary glomerular disease.
METHODS: An epidemiological survey was conducted to collect the data of 227 patients diagnosed as chronic primary glomerular diseases, and their severity of BSS were scored three days before renal biopsies were performed. The following clinical indexes were analyzed: age, course of glomerular diseases, 24-h urine protein ration (Upro), hypertension and blood pressure (BP) progress, serum creatinine levels (Scr), estimation of glomerular filtration rate based on the predigesting equation of MDRD (eGFR), blood urea nitrogen (BUN), uric acid (UA), triglyceride (TG), cholesterol (CHO), haematoglobin (HGB), albumin (ALB), and the correlation among renal pathological types, pathology lesion indexes, and BSS scores.
RESULTS: (1) Among the 227 patients, 207 (91.19%) were diagnosed as BSS, in which 95 cases were considered as moderate and the rest 112 cases as severe. (2) There was a negative correlation between age, gender, grades of the hypertension, and the BSS score. Multiple stepwise regression analysis showed that Upro, CHO, TG, and eGFR were positively related to the BSS score (P<0.05). (3) The BSS score has a positive correlation with indexes of chronic renal pathology, especially the tubular atrophy and interstitial fibrosis. The severity of proliferation and glomerular sclerosis was accompanied with higher BSS scores with a significant difference (P<0.05).
CONCLUSIONS: BSS is one of the most common CM syndromes among patients with the primary glomerular diseases; the BSS score has a positive correlation with Upro, CHO, TG, eGFR, as well as the index of chronic renal pathology. Based on these observations, the BSS may be used as an indicator of the development of renal diseases. Being positively diagnosed as BSS could indicate the beginning of the chronic phase of the primary glomerular diseases.

Entities:  

Mesh:

Year:  2009        PMID: 19568708     DOI: 10.1007/s11655-009-0170-4

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  11 in total

1.  [Study on the relationship between blood stasis syndrome and clinical pathology in patients with IgA nephropathy].

Authors:  Cheng-Yun Wei; Xiang-Mei Chen; Dan-Yang Zhao; Yongze Zhuang
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2005-08

2.  Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Jane Marsh; Lesley A Stevens; John W Kusek; Frederick Van Lente
Journal:  Clin Chem       Date:  2007-03-01       Impact factor: 8.327

3.  Predicting renal outcome in IgA nephropathy.

Authors:  M G Radford; J V Donadio; E J Bergstralh; J P Grande
Journal:  J Am Soc Nephrol       Date:  1997-02       Impact factor: 10.121

Review 4.  Understanding the nature of renal disease progression.

Authors:  G Remuzzi; P Ruggenenti; A Benigni
Journal:  Kidney Int       Date:  1997-01       Impact factor: 10.612

Review 5.  Tubulointerstitial changes as a major determinant in the progression of renal damage.

Authors:  K A Nath
Journal:  Am J Kidney Dis       Date:  1992-07       Impact factor: 8.860

6.  The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria.

Authors:  C C Szeto; F M Lai; K F To; T Y Wong; K M Chow; P C Choi; S F Lui; P K Li
Journal:  Am J Med       Date:  2001-04-15       Impact factor: 4.965

7.  [A multi-centeric epidemiological survey on TCM syndrome in 1016 patients with IgA nephropathy and analysis of its relevant factors].

Authors:  Xiang-Mei Chen; Yi-Ping Chen; Ping Li
Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi       Date:  2006-03

8.  Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy.

Authors:  James V Donadio; Erik J Bergstralh; Joseph P Grande; Diana M Rademcher
Journal:  Nephrol Dial Transplant       Date:  2002-07       Impact factor: 5.992

Review 9.  Von Willebrand factor in diabetic angiopathy.

Authors:  L Kessler; M L Wiesel; P Attali; J M Mossard; J P Cazenave; M Pinget
Journal:  Diabetes Metab       Date:  1998-09       Impact factor: 6.041

10.  Close relationship between microalbuminuria and insulin resistance in essential hypertension and non-insulin dependent diabetes mellitus.

Authors:  R Nosadini; M R Cipollina; A Solini; M Sambataro; A Morocutti; A Doria; P Fioretto; E Brocco; B Muollo; F Frigato
Journal:  J Am Soc Nephrol       Date:  1992-10       Impact factor: 10.121

View more
  4 in total

1.  An innovative method to accommodate Chinese medicine pattern diagnosis within the framework of evidence-based medical research.

Authors:  Christine Berle; Deirdre Cobbin; Narelle Smith; Christopher Zaslawski
Journal:  Chin J Integr Med       Date:  2011-11-06       Impact factor: 1.978

2.  Understanding and Therapeutic Strategies of Chinese Medicine on Gut-Derived Uremic Toxins in Chronic Kidney Disease.

Authors:  Chuan Guo; Xiang-Rong Rao
Journal:  Chin J Integr Med       Date:  2018-05-11       Impact factor: 1.978

Review 3.  Traditional Chinese Medicine in the Treatment of Chronic Kidney Diseases: Theories, Applications, and Mechanisms.

Authors:  Yunlai Wang; Ye Feng; Manman Li; Mo Yang; Gaoxiang Shi; Zihua Xuan; Dengke Yin; Fan Xu
Journal:  Front Pharmacol       Date:  2022-07-18       Impact factor: 5.988

4.  The Relationship between Stasis-Stagnation Constitution and Peripheral Arterial Disease in Patients with Type 2 Diabetes.

Authors:  Kuo-Chin Huang; Ching-Chu Chen; Yi-Chang Su; Jui-Shan Lin; Chwen-Tzuei Chang; Tzu-Yuan Wang; Rong-Hsing Chen; Fuu-Jen Tsai
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-11       Impact factor: 2.629

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.